Quarterly ResultApr 21, 2026, 04:04 PM
Beta Bionics Q1 Sales Up 57% to $27.6M, Raises FY26 Guidance
AI Summary
Beta Bionics reported strong first-quarter 2026 financial results, with net sales increasing 57% to $27.6 million, driven by a significant 181% surge in the Pharmacy Benefit Plan channel. The company also improved its gross margin by 864 basis points to 59.5%. Despite reporting a net loss of $21.9 million, Beta Bionics raised its full-year 2026 guidance for total revenue, PBP new patient starts, and gross margin, indicating a positive outlook for continued growth and efficiency.
Key Highlights
- Net sales increased 57% to $27.6 million in Q1 2026.
- Gross margin improved to 59.5%, up 864 basis points year-over-year.
- Full-year 2026 revenue guidance raised to $131 million to $136 million.
- Full-year 2026 gross margin guidance raised to 57.5% to 59.5%.
- Net loss was $21.9 million, an improvement from $28.7 million in Q1 2025.